Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Keytruda: metastatic cervical cancer with PD-L1 stated without a specific alteration after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test

Broader topic: Cervical Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    PD-L1
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approv
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for Keytruda (pembrolizumab) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
source wording
Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test

Study evidence for this setting

1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT04432597 · Registry condition search · Scope: unclear

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

6 outcome links · 4 safety-group records · 0 quality-of-life measures

→
Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice